A 8501

  • New York Assembly Bill
  • 2023 Regular Session
  • Introduced in Assembly
  • Passed Assembly Jan 16, 2024
  • Passed Senate Jan 29, 2024
  • Signed by Governor Feb 07, 2024

Relates to adverse determinations related to a step therapy protocol override determination; repealer

Abstract

Requires written notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination which includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent.

Bill Sponsors (1)

Votes


Actions


Feb 07, 2024

Assembly

DELIVERED TO GOVERNOR

Assembly

SIGNED CHAP.28

Jan 29, 2024

Senate

SUBSTITUTED FOR S8038

Senate

3RD READING CAL.38

Senate

PASSED SENATE

Senate

RETURNED TO ASSEMBLY

Jan 16, 2024

Assembly

PASSED ASSEMBLY

Assembly

DELIVERED TO SENATE

Senate

REFERRED TO RULES

Jan 11, 2024

Assembly

ADVANCED TO THIRD READING CAL.214

Jan 08, 2024

Assembly

REPORTED

Jan 04, 2024

Assembly

REFERRED TO INSURANCE

Bill Text

Bill Text Versions Format
A8501 PDF HTML

Related Documents

Document Format
No related documents.

Sources

Data on Open States is updated periodically throughout the day from the official website of the New York Legislature.

If you notice any inconsistencies with these official sources, feel free to file an issue.